PubRank

Gilles Edan

Author PubWeight™ 71.30‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005 24.22
2 Acute fulminant demyelinating disease: a descriptive study of 60 patients. Arch Neurol 2007 3.81
3 Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol 2011 3.52
4 Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009 3.42
5 Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007 3.29
6 Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010 2.63
7 Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011 2.19
8 Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007 2.06
9 Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007 1.89
10 Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012 1.46
11 Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol 2003 1.39
12 Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. Brain 2011 1.11
13 Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 2007 1.07
14 Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol 2008 1.07
15 Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. Arch Neurol 2007 1.01
16 Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. J Neurol 2007 0.96
17 Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Mult Scler 2012 0.91
18 Assessment of cognitive dysfunction in multiple sclerosis. J Neurol Sci 2006 0.91
19 Only physical aspects of quality of life are significantly improved by bilateral subthalamic stimulation in Parkinson's disease. J Neurol 2005 0.90
20 A role for VAV1 in experimental autoimmune encephalomyelitis and multiple sclerosis. Sci Transl Med 2009 0.90
21 Blood T-cell receptor beta chain transcriptome in multiple sclerosis. Characterization of the T cells with altered CDR3 length distribution. Brain 2004 0.89
22 Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. Arch Neurol 2009 0.86
23 Investigation of seven proposed regions of linkage in multiple sclerosis: an American and French collaborative study. Neurogenetics 2003 0.85
24 Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans. J Neuroimmunol 2006 0.85
25 Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. Mult Scler 2013 0.84
26 3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study. J Neurol 2010 0.83
27 Mitoxantrone therapy for acute posterior multifocal placoid pigment epitheliopathy with cerebral vasculitis. Case Rep Med 2009 0.82
28 Neurological Wilson's disease lethal for the son, asymptomatic in the father. Mov Disord 2013 0.81
29 Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay. Clin Chim Acta 2006 0.80
30 Genetic interaction of CTLA-4 with HLA-DR15 in multiple sclerosis patients. Ann Neurol 2003 0.80
31 Genetic analysis of multiple sclerosis in Europeans: French data. J Neuroimmunol 2003 0.79
32 Effects of pregnancy and child birth on urinary symptoms and urodynamics in women with multiple sclerosis. Int Urogynecol J Pelvic Floor Dysfunct 2005 0.78
33 Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study. J Neurol 2015 0.78
34 Long-term experience with induction treatment regimens in multiple sclerosis. J Neurol Sci 2009 0.78
35 [Neuropsychiatric manifestations in multiple sclerosis (MS): Might psychotic symptoms signal the onset of the disease?]. Presse Med 2013 0.77
36 Criteria improving multiple sclerosis diagnosis at the first MRI. J Neurol 2015 0.77
37 IFIH1-GCA-KCNH7 locus is not associated with genetic susceptibility to multiple sclerosis in French patients. Eur J Hum Genet 2009 0.76
38 Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay. Clin Chim Acta 2008 0.76
39 Improving the quality of life of multiple sclerosis patients through coping strategies in routine medical practice. Neurol Sci 2014 0.75
40 Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis. BMC Neurol 2014 0.75
41 MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome. BMC Neurol 2009 0.75
42 Choreic syndrome due to Hashimoto's encephalopathy. Mov Disord 2002 0.75
43 The effect of mitoxantrone on anti-pig immunization in baboons. Xenotransplantation 2003 0.75
44 Clinical and radiological characteristics in multiple sclerosis patients with large cavitary lesions. Eur Neurol 2012 0.75
45 [Drug therapy in multiple sclerosis]. Rev Prat 2006 0.75
46 An unusual cause of acute paraplegia in a 16-year-old dancer. J Neurol 2014 0.75
47 A model for a regional health information network sharing clinical information between professionals in Britanny. Stud Health Technol Inform 2006 0.75